Yahoo
NYSE American - Nasdaq Real Time Price USD

Protalix BioTherapeutics, Inc. (PLX)

2.5750 -0.0150 (-0.58%)
As of 12:46:29 PM EST. Market Open.
Trade PLX on Coinbase
Chart Range Bar
Loading chart for PLX
  • Previous Close 2.5900
  • Open 2.6000
  • Bid 2.5800 x 50000
  • Ask 2.5800 x 170000
  • Day's Range 2.5518 - 2.6200
  • 52 Week Range 1.6500 - 3.1900
  • Volume 201,337
  • Avg. Volume 785,421
  • Market Cap (intraday) 207.472M
  • Beta (5Y Monthly) -0.02
  • PE Ratio (TTM) 11.20
  • EPS (TTM) 0.2300
  • Earnings Date (est.) Nov 12, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 11.00
  • Motley Fool Rating Bearish

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack, New Jersey.

www.protalix.com

226

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

PLX
43.06%
S&P 500 (^GSPC)
11.06%

1-Year Return

PLX
8.65%
S&P 500 (^GSPC)
11.15%

3-Year Return

PLX
52.37%
S&P 500 (^GSPC)
76.08%

5-Year Return

PLX
127.88%
S&P 500 (^GSPC)
64.18%

Earnings Trends

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 19.9M
Earnings 3.78M
Profit Margin 18.98%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
10M
20M
30M
-60.0%
-40.0%
-20.0%
0.0%
20.0%
40.0%

Analyst Insights

View More

Analyst Price Targets

10.00
11.00 Average
2.5750 Current
12.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 9/9/2026
Analyst HC Wainwright & Co.
Rating Action Reiterates
Rating Buy
Price Action Maintains
Price Target 12 -> 12

Statistics

View More

Valuation Measures

Annual
As of 10/30/2026
  • Market Cap

    208.68M

  • Enterprise Value

    177.23M

  • Trailing P/E

    11.26

  • Forward P/E

    51.80

  • PEG Ratio (current)

    0.14

  • Price/Sales (ttm)

    2.61

  • Price/Book (mrq)

    2.92

  • Enterprise Value/Revenue

    2.20

  • Enterprise Value/EBITDA

    7.13

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    23.50%

  • Return on Assets (ttm)

    15.42%

  • Return on Equity (ttm)

    31.24%

  • Revenue (ttm)

    80.62M

  • Net Income Avi to Common (ttm)

    18.95M

  • Diluted EPS (ttm)

    0.2300

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    40.66M

  • Total Debt/Equity (mrq)

    12.89%

  • Levered Free Cash Flow (ttm)

    2.99M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

2.5750 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

Research Reports

View More
  • Daily – Vickers Top Buyers & Sellers for 12/24/2025

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

  • Daily – Vickers Top Buyers & Sellers for 10/23/2023

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

  • Daily – Vickers Top Buyers & Sellers for 01/06/2023

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

  • Daily – Vickers Top Buyers & Sellers for 04/14/2022

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: